An increased risk of LRR has been linked to a variety of clinicopathologic factors including patient age, tumor size and grade, LVI, the number of positive lymph nodes, bilateral breast cancer, ER/PR status, Ki67 proliferation index and the length of endocrine therapy [26–30]. This evidence concerns the gene ESR1 and breast cancer.